SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2019 and provided a Company update. “Daré made tremendous progress during the second quarter and remains
DARE-BV1 Phase 3 registrational trial initiation expected in 4th quarter 2019 SAN DIEGO , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing clindamycin phosphate 2%,
DARE-BV1 is a proprietary formulation of clindamycin phosphate 2% for vaginal administration as a potential new first-line treatment for bacterial vaginosis SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the
SAN DIEGO , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 14, 2019 , to review the Company's financial results for the
DARE-HRT1 is a potential treatment of menopause-related symptoms DARE-FRT1 is a potential pregnancy maintenance therapy SAN DIEGO , July 22, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting two posters at
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone receptor-positive breast cancer SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
SAN DIEGO , July 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter , Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019 .
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive SAN DIEGO, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its
SAN DIEGO , June 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019 , starting at 11:15
